TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Tg levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: iodine uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: frequency of postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical/endoscopic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rates of remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Food intake
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: progressive radiographic damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: color stability of maxillofacial silicone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QTc interval change per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of dapivirine vaginal ring
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetic profile of dapivirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the RTW coordinator
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk of clinical visceral leishmaniasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: feasibility of procedures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FACT Fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall clinical efficacy in measuring pyuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: taste
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse effects documented in the medical record
Endpoint domain: Adverse events/effects
Primary endpoint: Patients discontinued with documented adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Perceptual and quality-of-life measures
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Interobserver and intraobserver agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient participation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement in behavioral outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PS)
Endpoint domain: Mortality/survival
Primary endpoint: Loco-Regional Recurrence (LRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean wound healing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived soreness
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: time in play
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower-body power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term local response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean radiation doses of the TMJ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMJ injuries according to SOMA criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of pneumothorax
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of chest tube placement
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of postprocedure hospital admission
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cardiac output with Trendelenburg positioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30-day composite end point
Endpoint domain: Mortality/survival
Primary endpoint: Suicidal risk
Endpoint domain: Adverse events/effects
Primary endpoint: Suicidal plans and attempts
Endpoint domain: Adverse events/effects
Primary endpoint: Dropout rate
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: peak concentric force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PTSD frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cocaine and alcohol use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful cryorecanalization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean survival time after cryorecanalization
Endpoint domain: Mortality/survival
Primary endpoint: Rhinitis and asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medicine scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence of amlodipine formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of reflux episodes/hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinical pregnancies obtained
Endpoint domain: Mortality/survival
Primary endpoint: actuarial survival after 12 years
Endpoint domain: Mortality/survival
Primary endpoint: incidence of reoperation after 12 years
Endpoint domain: Mortality/survival
Primary endpoint: bleeding requiring hospitalization or blood transfusion after 12 years
Endpoint domain: Adverse events/effects
Primary endpoint: Antibacterial effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: prevention of death
Endpoint domain: Mortality/survival
Primary endpoint: need for dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: persistent decline in kidney function at 90 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: RV end-diastolic area index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Viral decay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel preparation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TnT serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: hospital deaths
Endpoint domain: Mortality/survival
Primary endpoint: LDL particle diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VLDL triglycerides concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in low-density lipoprotein cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum FDKP AUC0-240 min ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events including hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: defaecatory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic anastomotic leakage
Endpoint domain: Adverse events/effects
Primary endpoint: successful outcome of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Mean Midexpiratory Flow Rate (FEF25‐75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Complete response of actinic keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain during illumination
Endpoint domain: Adverse events/effects
Primary endpoint: Stereoacuity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased risk of TB transmission
Endpoint domain: Mortality/survival
Primary endpoint: sneezing frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nose-blowing frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal congestion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients surviving at two years
Endpoint domain: Mortality/survival
Primary endpoint: Median survival time for patients with CHF
Endpoint domain: Mortality/survival
Primary endpoint: anti-cancer activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: grade 3/4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of robust response to methylphenidate vs. atomoxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasminogen activator inhibitor-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tissue plasminogen activator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lung cancer risk associated with SP-D levels
Endpoint domain: Mortality/survival
Primary endpoint: Lung cancer risk associated with KL-6 levels
Endpoint domain: Mortality/survival
Primary endpoint: Ambulation preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peakVO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: repeat MBE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viable cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in stimulant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving abstinence from stimulant use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lp(a) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: HDLc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Attendance at 9 or more classes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Attendance at 16 or more classes
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Prescribing of first-generation antipsychotic drugs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: anti-HAV antibody seropositivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-HBs antibody levels > or = 10 mIU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Physical HRQL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental HRQL
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Work of Breathing (WOB(I))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung Compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: satisfaction with sexual enjoyment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: frequency of sexual life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: enjoyment of sexual life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PANSS Total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PANSS-FSNS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PSP Total score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Completion of XR-NTX induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response (SVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain and discomfort during injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in populations of Bifidobacterium spp. and Lactobacillus spp.
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decrease in population of coliform organisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cytokine recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: adherence to strength-training exercises
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low-density lipoprotein cholesterol (LDL) particle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean severity score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Psoriasis Area and Severity Index score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of diabetic complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deterioration in retinopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: risk of smoking relapse
Endpoint domain: Mortality/survival
Primary endpoint: Rate of study discontinuation due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with cardiovascular/renal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with hepatic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain management activities implementation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of adenomas ≤5 mm in size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence rate of allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication Harm Reduction Points (MHRPs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean fentanyl plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T(max) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from arrhythmia recurrences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in SF-36 quality of life scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of leg cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kidney and patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Q max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collaborative care depression services
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAScog score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient-physician interactions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Mean bond strength in cervical root region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in time of onset of VMO EMG compared with VL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bleeding and gingival index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative microbial growth for S mutans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Laboratory-confirmed influenza infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lower respiratory tract involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Seroconversion based on serum neutralizing activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bloodstain to surgical wound size ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: subjective hemostasis assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in-stent late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in fine lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in coarse wrinkles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average actinic keratosis clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Objective success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in omeprazole use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in metronidazole use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Mini-Mental State Examination scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Likelihood of cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: IIEF-5 score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant abnormality in electrocardiograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Subjective decrease of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: tooth eruption intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptability of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Moxifloxacin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAPID3 patient-only index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Screening for major depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Geometric mean flea count reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of flea-free primary dogs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in veterinarian assessed flea allergy dermatitis (FAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in EC occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Measure of Audiologic Rehabilitation Self‐Efficacy for Hearing Aids
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: utility task performance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Choroidal neovascularization incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean correlation of energy and nutrients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeatability of Web‐PDHQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of eSET
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Levels of IU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MS acceptance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Physical Health Component of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Medication appropriateness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retrieval of long-term emotional memories
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Awakening response improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uninhibited contractions (UIC) cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower leg volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life: leg complaints
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AIMS mean score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-TD score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AIMS responder rates (≥50% score reduction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of obesity (BMI ≥ 30 kg/m2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of type 2 diabetes mellitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of central obesity (waist circumference exceeding IDF threshold)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: smoke-free status at 2 years
Endpoint domain: Mortality/survival